Cyrus Biotechnology Appoints Dr. David A Pearlman as Senior Fellow and Director of Customer Experience

Cyrus technology can speed new drug discovery

SEATTLE, WA November 20, 2017 — Cyrus Biotechnology, a biotechnology software company offering first-in-class tools for advanced protein modeling and discovery in drug development, announced today that it has appointed David Pearlman, Ph.D. as Senior Fellow and Director of Customer Experience.  Dr. Pearlman will lead scientific customer interactions with Cyrus’s client firms in pharmaceuticals, biotechnology therapeutics, synthetic biology and consumer products, creating a unified customer experience team. Dr. Pearlman’s team will guide users towards creating enhanced value through new engineered proteins and other compounds for a wide variety of indications using Cyrus technology.  Prior to joining Cyrus, Dr. Pearlman’s industry role was Senior Scientist and Director of Biologics Software Platform at Schrödinger, LLC, a leader in chemical simulation software and services.

 

“David has a track record of scientific innovation and market-savvy product creation in molecular modeling software that is unique. We are very fortunate to add him to our leadership team at Cyrus”, said Dr. Lucas Nivon, CEO of Cyrus. “He has played a critical role in the creation and growth of a number of innovative and market-leading firms, and has the unique blend of deep scientific understanding and customer-centric product development that will be important for Cyrus as we engage with a rapidly expanding set of customers.”

 

“The ability of computational chemistry to make significant contributions to molecular discovery has grown tremendously over my career.” said Dr. Pearlman.  “We’re now at a point where understanding, methods and computational resources are having real, measurable impact on new drug discovery. I’m particularly excited to be at Cyrus, where we are commercializing the world-class Rosetta protein design tools. The Rosetta platform has been at the heart of an incredible number of defining protein design studies over the past couple of decades.” Pearlman added.

 

Dr. Pearlman is a pioneer in the field of computational chemistry. He was a founding product manager at Biosym Technologies (later BIOVIA), an early employee of Vertex Pharmaceuticals, and led development of the biologics software platform (BioLuminate) at Schrödinger, LLC. He was also, for many years, first author and a principal developer of the widely-used AMBER simulation platform. He has published a long string of seminal papers in the area of free energy perturbation, and extensively on topics such as NMR refinement and de novo ligand design and scoring.

 

Background

Cyrus Biotechnology

Cyrus Biotechnology, Inc. is a privately-held biotechnology software company offering protein modeling and design capabilities to the Biopharmaceutical, Chemical, Consumer Products and Synthetic Biology industries. Cyrus was founded in 2014 as a spin-out from the University of Washington, and offers Cyrus Bench®, a Software-as-a-Service (SaaS) platform for protein structure prediction, modeling, stabilization, engineering and design to accelerate discovery of Biologics and Small Molecules. Cyrus Bench is based primarily on the Rosetta software package from Prof. David Baker’s lab at the University of Washington, along with associated software. Cyrus Bench offers the world-leading protein structure prediction pipeline of Rosetta and SparksX, the top structure prediction software in the bi-annual CASP competition and the weekly CAMEO competition, as well as the only protein engineering software experimentally proven to design new proteins completely via software. Cyrus Bench is based on over 15 years of biochemistry software development and over 400 published papers demonstrating experimental efficacy in vitro and in vivo. Cyrus is funded by experienced investors in Tech and Biotech including Trinity Ventures, Orbimed Advisors, SpringRock Ventures, W Fund and others…

 

NOTICE: The information contained in this document is dated as of November 20, 2017.  Cyrus Biotechnology, Inc. (the Company) disclaims any obligation to update such information after such date.  This document contains forward–looking statements reflecting the Company’s current expectations that necessarily involve risks and uncertainties.  Actual results and the timing of events may differ materially from those contained in such forward-looking statements due to a number of factors and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

 

Cyrus Press Release 11/20/2017

 

Contact Lucas Nivon
lucas@cyrusbio.com
206-258-6561

 

Cyrus Bio Featured in US Pharmaceutical Industry Weekly Report

Cyrus Bio CEO, Lucas Nivon, was interviewed by MSA Partners for the October 20, 2017 issue of the US Pharmaceutical Industry Weekly Report. Please contact MSA Partners to subscribe to the newsletter.

About MSA Partners
Founded in 1983, MSA Partners’ mission is to provide Japanese organizations with means and ways to realize and grow their business potential in the US market. As the challenges faced by Japanese organizations doing business in the US have grown increasingly complex over the years, MSA’s integrated and creative approach has become ever more valuable to its clients. MSA takes a team-based approach to combine the skills and expertise of both American and Japanese professionals from MSA, supplement these with outside skills when necessary, and work closely with clients to accomplish their goals. With over 25 years of experience, MSA offers a diverse range of interrelated research, consulting, communications and positioning services, to provide in-depth, comprehensive support to clients. Recognizing that one of the keys to quickly seizing market opportunities is overcoming organizational and language barriers, MSA’s ability to seamlessly interface with our clients at both the head office and US subsidiary level facilitates shared understanding and decision-making.

Cyrus Bio Leads Computational Protein Engineering Panel

SEATTLE, October 17, 2017 — Lucas Nivon, CEO of Cyrus Biotechnology, today will lead a panel on recent advances in computational protein engineering at LabCentral in Cambridge, MA.

 

Computationally designed therapeutic proteins are in the clinic, and computationally optimized enzymes are producing ingredients of value sustainably and cost effectively. Dr. Nivon will present an overview of published and experimentally verified advances in computational protein engineering, and will demonstrate some modeling workflows with sample software based on the Rosetta protein modeling toolkit first developed at Professor David Baker’s laboratory at the University of Washington. Following Dr. Nivon’s overview, four panelists from Manus Biosynthesis, Moderna Therapeutics, Northeastern University and UMass Dartmouth will present various examples of protein modeling.

 

In addition to LabCentral, this event has been publicized on Mass Bio and Mass Life Sciences Center web sites.

 

Click here for registration and full abstracts.

Cyrus Biotechnology Announces $8M Financing to Expand Computational Drug Discovery Software Platform

 

Bench® software increases access to cutting edge technology which can speed design and development of new therapies, consumer products

 

Seattle, WA July 27, 2017 — Cyrus Biotechnology, Inc., a Seattle-based biotechnology software firm offering an advanced computational tool for protein modeling and design to accelerate new drug discovery, today announced the closing of an $8M total Series A financing. The investment was led by Trinity Ventures, with participation from OrbiMed Advisors, SpringRock Ventures, W Fund and individual investors.

 

Cyrus Bench® software is based on years of work in computational biophysics and the first software algorithms to design new proteins in a computer. It accelerates drug discovery at pharmaceutical and biotechnology firms, as well as new product development at synthetic biology, chemical and consumer products firms. Bench® is a graphical, cloud-enabled version of the Rosetta protein modeling toolkit. Data generated from Rosetta technology can be used in the design of new potential therapeutics, such as a therapeutic protein of Tocagen’s Toca 511 and PVP Biologics’ KumaMax, an oral enzyme.

 

“We are very excited to close this first institutional financing round with such knowledgeable, high-caliber biotech and high-tech investors,” said Cyrus CEO Dr. Lucas Nivon. “The new funding validates our business plan and allows us to expand the capabilities and opportunities of this cutting-edge platform. Our Bench® technology broadens access to the most advanced computational methods, giving more scientists the means to speed their research and save costs. The result will be more effective drugs getting to patients sooner.”

 

Cyrus offers Bench®, a Software-as-a-Service platform for protein structure prediction, discovery, modeling, stabilization, engineering and design, along with custom software development and experienced scientific support services in computational protein engineering. Bench® has been designed to make this technology more user-friendly and for a wider range of users than previous academic-based software. Cyrus launched a software beta in 2016 with initial release in early 2017, and has rapidly acquired customers ranging from Fortune 500 Pharma (including seven of the top 20 Pharma firms), chemical and consumer products firms to privately-held biotech and synthetic biology firms.

 

“We are very excited to bring Cyrus Bench to a wide variety of customers, from blue chip Pharma firms to tiny startups, to truly democratize computational protein engineering and lower the cost of entry, as we have seen happen in software tech,” said Gus Tai, General Partner at Trinity Ventures who will join the Board of Directors, along with Eric Bell at SpringRock.

 

Carl Gordon of OrbiMed Advisors added, “I think Cyrus software will accelerate early therapeutics discovery in many organizations, especially at biologics focused biotech firms that are not currently benefitting from new biotech algorithms and software.”

 

 

About Cyrus Biotechnology and Cyrus Bench®

Cyrus Biotechnology, Inc. is a privately-held biotechnology software company offering protein modeling and design capabilities to the biopharmaceutical, chemical, consumer products and synthetic biology industries. The company offers Cyrus Bench®, a Software-as-a-Service (SaaS) platform for protein structure prediction, modeling, stabilization, and engineering and design to accelerate discovery of biologics and small molecules. Cyrus Bench® is based primarily on the Rosetta software package, along with associated software. Cyrus Bench® offers the advanced protein structure prediction pipeline of Rosetta and SparksX, the top structure prediction software in the bi-annual CASP competition (last held in 2016) and the weekly, continuous CAMEO competition, as well as the only protein engineering software experimentally proven to design new proteins completely via software.  For more information about Cyrus and Bench® please visit our website https://www.cyrusbio.com/

 

 

NOTICE: The information contained in this document is dated as of July 27, 2017.  Cyrus Biotechnology, Inc. (the Company) disclaims any obligation to update such information after such date.  This document contains forward–looking statements reflecting the Company’s current expectations that necessarily involve risks and uncertainties.  Actual results and the timing of events may differ materially from those contained in such forward-looking statements due to a number of factors and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

 

 

Contact Lucas Nivon

lucas@cyrusbio.com

206-258-6561

 

 

About Trinity Ventures

Trinity Ventures is a top-tier venture capital firm combining business insight, practical expertise and a personal touch to help start-ups win big. For over thirty years, Trinity has helped passionate entrepreneurs with breakthrough ideas transform markets and lives. Trinity’s investment team takes a collaborative approach and believes in personal engagement, mutual respect and goal alignment to deliver out-sized returns to entrepreneurs and investors. The firm invests in early stage technology companies with emphases on Cloud and Mobile infrastructure, Software-as-a-Service, Digital Media and Social Commerce and Entertainment. To learn more visit: www.trinityventures.com.

 

About OrbiMed

OrbiMed is a leading investment firm dedicated exclusively to the healthcare sector, with over $14 billion in assets under management. OrbiMed invests globally across the spectrum of healthcare companies, from venture capital start-ups to large multinational companies utilizing a range of private equity funds, public equity funds, royalty/debt funds and other investment vehicles. OrbiMed maintains its headquarters in New York City, with additional offices in San Francisco, Shanghai, Mumbai and Herzliya.

OrbiMed seeks to be a capital provider of choice, with the flexibility to provide equity and debt capital solutions that are tailored to the unique needs of our portfolio companies. The firm’s global team of over 80 professionals brings the resources and experience required to be an exceptional long-term partner in building world-class healthcare companies. www.OrbiMed.com.

About SpringRock

SpringRock Ventures (www.springrockventures.com) was founded with the perspective that healthcare and information technology are converging.  The fund invests in the next cycle of health innovation including SaaS, devices, precision medicine, services, and other disruptive technologies. SpringRock invests in all stages, up to $5 million per portfolio company, and invests throughout North America.  The fund’s investment partners have collectively invested in 25+ venture-backed companies with 15+ successful financial exits.  SpringRock’s portfolio includes Cyrus Biotechnology, CSATS and Carrum Health.

Cyrus Biotechnology Exhibits at the PEGS Protein Engineering Summit in Boston, May 1st-4th

SEATTLE, April 20, 2017 — Cyrus Biotechnology, Inc., a new biotechnology software company offering the most advanced protein modeling and design capabilities to the Biopharmaceutical, Synthetic Biology, Chemical, and Consumer Products industries is pleased to announce its participation in the 13th Annual PEGS Boston Protein Engineering Summit in Boston, from May 1st through May 4th.

Dr. Yifan Song, Chief Science Officer at Cyrus Bio, and Rosario Caltabiano, Executive VP of Sales, will attend the conference and discuss the latest advances in in silico protein engineering at booth 503 in the Boston Seaport World Trade Center Exhibit Hall.

The Rosetta software package, from the RosettaCommons, is the premier software platform for advanced computational protein engineering. Cyrus has implemented the Rosetta stack with an easy to use interface on a public computing cloud, resulting in high reliability software with high performance and usability in a secure multi-tenant model. R&D organizations can remove large capital expenditures, avoid over- or under-provisioning, and maximize scientific output.

In silico modeling and design of proteins is becoming increasingly relevant to the pharmaceutical industry, as investment in research, development and clinical trials of biologic therapeutics continues to grow. Cyrus Bench® software, and the underlying Rosetta software package, are already leveraged by many global pharmaceutical organizations and are at the nexus of this major trend. Cyrus customers can apply the most advanced and validated in silico protein engineering science through an intuitive user interface for:

 

  • Protein Structure Prediction (best overall performance at CASP and CAMEO)
  • Protein Stabilization (single point mutants, multiple point mutants, evolutionary redesign)
  • Protein / Protein Interface Design
  • Protein Design (modifications to function or structure)
  • Enzyme Optimization

 

Background

Cyrus Biotechnology

Cyrus Biotechnology, Inc. is a new privately-held biotechnology software company offering protein modeling and design capabilities to the Biopharmaceutical, Chemical, Consumer Products and Synthetic Biology industries. Cyrus was founded in 2014 as a spin-out from the University of Washington, and offers Cyrus Bench®, a Software-as-a-Service (SaaS) platform for protein structure prediction, modeling, stabilization, engineering and design to accelerate discovery of Biologics and Small Molecules. Cyrus Bench® is based primarily on the Rosetta software package from Prof. David Baker’s lab at the University of Washington, along with associated software. Cyrus Bench® offers the world-leading protein structure prediction pipeline of Rosetta and SparksX, the top structure prediction software in the bi-annual CASP competition and the weekly CAMEO competition, as well as the only protein engineering software experimentally proven to design new proteins completely via software. Cyrus Bench® is based on over 15 years of biochemistry software development and over 400 published papers demonstrating experimental efficacy in vitro and in vivo.

 

NOTICE: The information contained in this document is dated as of April 19, 2017.  Cyrus Biotechnology, Inc. (the Company) disclaims any obligation to update such information after such date.  This document contains forward–looking statements reflecting the Company’s current expectations that necessarily involve risks and uncertainties.  Actual results and the timing of events may differ materially from those contained in such forward-looking statements due to a number of factors and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

 

Cyrus Press Release 04/20/2017

 

Cyrus Biotechnology Presents Implementation of Biocomputing on the Cloud at the American Chemical Society Spring Meeting in San Francisco

SEATTLE, April 3, 2017 — Cyrus Biotechnology, Inc., a new biotechnology software company offering the most advanced protein modeling and design capabilities to the Biopharmaceutical, Synthetic Biology, Chemical, and Consumer Products industries is pleased to announce its participation to the American Chemical Society Spring Meeting in San Francisco on April 3rd, 2017.

Dr. Lucas Nivon, CEO of Cyrus Bio, will speak about Cyrus’s journey of deploying the Rosetta software on the cloud and share lessons learned. The Rosetta software, from the RosettaCommons, is the premier software platform for advanced computational protein engineering. It is a very complex software stack that requires years to learn in depth, is difficult to document, and is constantly in flux as new scientific features are created.

Cyrus has implemented the Rosetta stack on a public computing cloud, resulting in higher quality software with far higher performance in a secure multi-tenant model. R&D organizations can remove large capital expenditures, avoid over- or under-provisioning, and maximize scientific output.

Scripting or computing queues are no longer needed for structural biologists and biochemists who want to do protein design or modeling without having advanced computational skills.

Scientific computing is diverse, requires high performance and does not trivially extend to the cloud. It requires cloud-based systems architected specifically for scientific computing, using modern web technologies and frameworks, such as high performance web frontends and backend job provisioning.

In silico modeling and design of proteins is becoming increasingly relevant to the pharmaceutical industry, as investment in research, development and clinical trials of biologic therapeutics continue to grow. Cyrus Bench® software, and the underlying Rosetta software package, are already leveraged by many global pharmaceutical organizations and are at the nexus of this major trend. Cyrus customers can apply the most advanced and validated in silico protein engineering science through an intuitive user interface for:

 

  • Protein Structure Prediction (best overall performance at CASP and CAMEO)
  • Protein Stabilization (single point mutants, multiple point mutants, evolutionary redesign)
  • Protein / Protein Interface Design
  • Protein Design (modifications to function or structure)
  • Enzyme Optimization

Cyrus Bio wishes to thank Dr. Veerabahu Shanmugasundaram, one of the session’s organizers, for his kind invitation to speak at the Meeting.

 

Background

Cyrus Biotechnology

Cyrus Biotechnology, Inc. is a new privately-held biotechnology software company offering protein modeling and design capabilities to the Biopharmaceutical, Chemical, Consumer Products and Synthetic Biology industries. Cyrus was founded in 2014 as a spin-out from the University of Washington, and offers Cyrus Bench®, a Software-as-a-Service (SaaS) platform for protein structure prediction, modeling, stabilization, engineering and design to accelerate discovery of Biologics and Small Molecules. Cyrus Bench® is based primarily on the Rosetta software package from Prof. David Baker’s lab at the University of Washington, along with associated software. Cyrus Bench® offers the world-leading protein structure prediction pipeline of Rosetta and SparksX, the top structure prediction software in the bi-annual CASP competition and the weekly CAMEO competition, as well as the only protein engineering software experimentally proven to design new proteins completely via software. Cyrus Bench® is based on over 15 years of biochemistry software development and over 400 published papers demonstrating experimental efficacy in vitro and in vivo.

 

NOTICE: The information contained in this document is dated as of January 10, 2017.  Cyrus Biotechnology, Inc. (the Company) disclaims any obligation to update such information after such date.  This document contains forward–looking statements reflecting the Company’s current expectations that necessarily involve risks and uncertainties.  Actual results and the timing of events may differ materially from those contained in such forward-looking statements due to a number of factors and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

 

Cyrus Press Release 04/03/2017

Cyrus Biotechnology supports the Boston Area Group for Informatics and Modeling

SEATTLE and BOSTON, January 10, 2017 — Cyrus Biotechnology, Inc., a new biotechnology software company offering the most advanced protein modeling and design capabilities to the Biopharmaceutical, Synthetic Biology, Chemical, and Consumer Products industries is pleased to support the Boston Area Group for Informatics and Modeling (BAGIM).

With over 700 members and 17 industrial sponsors, BAGIM is one of the most preeminent and active professional communities in the Boston area, focusing on computer based modeling, facilitating information exchange and networking through presentations of scientific relevance by luminaries from industry and academia. In 2016, BAGIM has hosted nine well attended scientific presentations and networking events and continues to maintain an active presence on social media such as LinkedIn, Meetup, and Facebook.

In silico modeling and design of proteins is becoming increasingly relevant to the pharmaceutical industry, as investment in research, development and clinical trials of biologic therapeutics continue to grow. Cyrus Bench software, and the underlying Rosetta software package, are already leveraged by many global pharmaceutical organizations and are at the nexus of this major trend. Cyrus customers can apply the most advanced and validated in silico protein engineering science through an intuitive user interface for:

  •  Protein Structure Prediction (best overall performance at CASP and CAMEO)
  •  Protein Stabilization (single point mutants, multiple point mutants, evolutionary redesign)
  •  Protein / Protein Interface Design
  •  Protein Design (modifications to function or structure)
  •  Enzyme Optimization

Cyrus is pleased to support BAGIM ‘s efforts to advance biological informatics and modeling. Sponsorship from Cyrus will contribute to BAGIM expenses related to its educational/networking initiative centered around a lecture series.

Background

BAGIM (Boston Area Group for Informatics and Modeling)

BAGIM is an active community of Boston area scientists bringing together people from diverse fields of modeling and informatics to impact life and health sciences. BAGIM strives to create a forum for great scientific discussions covering a wide range of topics including data management, visualization, computational chemistry, drug discovery, protein structure, molecular modeling, structure-based drug design, data mining, software tools, and the sharing of goals and experiences. Our community is made up of participants from academia, government, and/or industry whose goal is to engage in the discussion of science involving a synthesis of theory and technology. Discussions sponsored by BAGIM are targeted to the needs and interests of informatics scientists, computational chemists, medicinal chemists, and statisticians. BAGIM also provides opportunities for networking within these disciplines as well as an arena for the dissemination of information of specific interest to the membership.

Cyrus Biotechnology

Cyrus Biotechnology, Inc. is a new privately-held biotechnology software company offering protein modeling and design capabilities to the Biopharmaceutical, Chemical, Consumer Products and Synthetic Biology industries. Cyrus was founded in 2014 as a spin-out from the University of Washington, and offers Bench, a Software-as-a-Service (SaaS) platform for protein structure prediction, modeling, stabilization, engineering and design to accelerate discovery of Biologics and Small Molecules. Cyrus Bench is based primarily on the Rosetta software package from Prof. David Baker’s lab at the University of Washington, along with associated software. Cyrus Bench offers the world-leading protein structure prediction pipeline of Rosetta and SparksX, the top structure prediction software in the bi-annual CASP competition and the weekly CAMEO competition, as well as the only protein engineering software experimentally proven to design new proteins completely via software. Cyrus Bench is based on over 15 years of biochemistry software development and over 400 published papers demonstrating experimental efficacy in vitro and in vivo.

 

NOTICE: The information contained in this document is dated as of January 10, 2017. Cyrus Biotechnology, Inc. (the Company) disclaims any obligation to update such information after such date. This document contains forward–looking statements reflecting the Company’s current expectations that necessarily involve risks and uncertainties. Actual results and the timing of events may differ materially from those contained in such forward-looking statements due to a number of factors and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

 

Cyrus Press Release 2017.01.10

Cyrus Biotechnology CEO to Unveil Cyrus Bench software for Protein Modeling and Design

SEATTLE, WA, December 20, 2016 — Cyrus Biotechnology, Inc., a new biotechnology software company offering the most advanced protein modeling and design capabilities to the Biopharmaceutical, Synthetic Biology, Chemical, and Consumer Products industries is presenting at the Biotech Showcase January 9 at 5:15PM in San Francisco.

Dr. Lucas Nivon, CEO of Cyrus, will present an overview of the Cyrus Bench software package, which is already used by customers in the BioPharma and Chemical industries including many Fortune 500 firms. The presentation will show use cases based on real customer examples, and highlight the impact that Cyrus Bench can make in accelerating product discovery.

Cyrus Bench automates the Rosetta software suite developed by the RosettaCommons consortium. Bench makes the most advanced biotechnology software available to most industry users for the very first time. Cyrus customers can apply the most advanced and validated in silico protein engineering science through an intuitive user interface for:

 

  • Protein Structure Prediction (best overall performance at CASP and CAMEO)
  • Protein Stabilization (single point mutants, multiple point mutants, evolutionary redesign)
  • Protein / Protein Interface Design
  • Protein Design (modifications to function or structure)
  • Enzyme Optimization

Background

Cyrus Biotechnology

Cyrus Biotechnology, Inc. is a new privately-held biotechnology software company offering protein modeling and design capabilities to the Biopharmaceutical, Chemical, Consumer Products and Synthetic Biology industries. Cyrus was founded in 2014 as a spin-out from the University of Washington, and offers Bench, a Software-as-a-Service (SaaS) platform for protein structure prediction, modeling, stabilization, engineering and design to accelerate discovery of Biologics and Small Molecules. Cyrus Bench is based primarily on the Rosetta software package from Prof. David Baker’s lab at the University of Washington, along with associated software. Cyrus Bench offers the world-leading protein structure prediction pipeline of Rosetta and SparksX, the top structure prediction software in the bi-annual CASP competition and the weekly CAMEO competition, as well as the only protein engineering software experimentally proven to design new proteins completely via software. Cyrus Bench is based on over 15 years of biochemistry software development and over 400 published papers demonstrating experimental efficacy in vitro and in vivo.

NOTICE: The information contained in this document is dated as of 12/20/2016.  Cyrus Biotechnology, Inc. (the Company) disclaims any obligation to update such information after such date.  This document contains forward–looking statements reflecting the Company’s current expectations that necessarily involve risks and uncertainties.  Actual results and the timing of events may differ materially from those contained in such forward-looking statements due to a number of factors and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Cyrus Press Release 2016.12.20

Cyrus CSO Yifan Song publishes advance in CryoEM Structure

Cyrus CSO Yifan Song, along with lead author Ray Wang from the University of Washington and PI Frank DiMaio have published an important next step in the progress towards making Cryo-Electron Microscopy (cryo-EM) a vital new tool in drug discovery. In their manuscript published in the journal eLife, “Automated structure refinement of macromolecular assemblies from cryo-EM maps using Rosetta”, Wang and co-authors describe a method in Rosetta software to automatically build atomic resolution models of complex protein assemblies from cryo-EM data. Cryo-EM technology has improved drastically in recent years due to new detector technology, allowing this method to approach atomic resolution. Atomic resolution is vital in solving protein structures, and structures are a linchpin in the discovery of most modern drugs. Without Rosetta, cryo-EM models from the new detectors are valuable, but with Rosetta automated structure building of atomic-resolution models, these data are drastically more useful in solving important medical problems.

https://elifesciences.org/content/5/e17219